Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Inventory Turnover : 0.00 (As of Dec. 2020)

View and export this data going back to 2005. Start your Free Trial

What is Sunesis Pharmaceuticals Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Sunesis Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2020 was $0.00 Mil. Sunesis Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2020 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sunesis Pharmaceuticals Inventory Turnover Historical Data

The historical data trend for Sunesis Pharmaceuticals's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Inventory Turnover Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Inventory Turnover

Get a 7-Day Free Trial

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Inventory Turnover	Get a 7-Day Free Trial															-	-	-	-	-

Sunesis Pharmaceuticals Inventory Turnover Calculation

Sunesis Pharmaceuticals's Inventory Turnover for the fiscal year that ended in Dec. 2020 is calculated as

	Inventory Turnover (A: Dec. 2020 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (A: Dec. 2020 )	/ (	(Total Inventories (A: Dec. 2019 )	+	Total Inventories (A: Dec. 2020 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Sunesis Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2020 is calculated as

	Inventory Turnover (Q: Dec. 2020 )
=	Cost of Goods Sold	/	Average Total Inventories
=	Cost of Goods Sold (Q: Dec. 2020 )	/ (	(Total Inventories (Q: Sep. 2020 )	+	Total Inventories (Q: Dec. 2020 ))	/	count )
=	0	/ (	(0	+	0)	/	1 )
=	0	/	0
=	N/A

Sunesis Pharmaceuticals (NAS:SNSS) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sunesis Pharmaceuticals's Days Inventory for the three months ended in Dec. 2020 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2020 )	/	Cost of Goods Sold (Q: Dec. 2020 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sunesis Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2020 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2020 )	/	Revenue (Q: Dec. 2020 )
	=	0	/	0
	=

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

Sunesis Pharmaceuticals Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (Sunesis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (NAS:SNSS) » Definitions » Inventory Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Executives

Steve Carchedi	director	210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Nicole Onetto	director	58 S SERVICE RD, MELVILLE NY 11747
Henry Ward Wolff	director	6701 KAISER DRIVE, FREMONT CA 94555
Steven B Ketchum	director	2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
James W Young	director
Homer L Pearce	director	84 CLIFDEN, ZIONSVILLE IN 46077
Dayton Misfeldt	director, officer: See Remarks	C/O BAY CITY CAPITAL LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
David C Stump	director
Tina Gullotta	officer: VP, Finance	SUNESIS PHARMACEUTICALS,INC, 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William P. Quinn	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Judith A. Fox	officer: See Remarks	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Aisling Capital Iv, Lp	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Aisling Capital Partners Iv Llc	10 percent owner	888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106